Predictive Molecular Biomarkers in Targeted Therapy of Gastric Carcinoma and Metastatic Colorectal Carcinoma

Full Article


Hong Kong J Radiol 2012;15(Suppl):S40-5

With the recent advancement of molecular targeting therapy, we are witnessing a paradigm shift in the role of pathology laboratories in the management of solid tumours. Pathologists not only continue to provide accurate pathological diagnosis and prognostic information, but also incorporate information about predictive biomarkers in the guidance of individualised treatment. Predictive biomarker study has become increasingly important to clinicians in formulating personalised therapies for their patients. Accurate determination of these predictive biomarkers has become the expected standard of care for cancer patients. Tailoring therapeutic regimens for advanced gastric carcinoma and metastatic colorectal carcinoma demonstrate the inevitable obligations for predicative biomarker study in the overall management of individual patients. In this review, we will discuss the biomarker analysis of HER2 status in advanced gastric carcinoma and KRAS mutation in metastatic colorectal carcinoma. Issues related to these biomarker determinations in the application of targeted therapy are illustrated.





隨著分子標靶治療不斷進步,我們對病理學實驗室在腫瘤治療中的角色有著思考模式的轉移。病理 學醫生不只繼續提供準確的病理學診斷及預後資料,更能加入預測性生物標記來引導個別的治療方 案。預測性生物標記在醫生為病人制定個人化的治療方案中相當重要,其精確的測定已成為癌症病 人的護理標準。為晚期胃腺癌和轉移性大腸癌患者度身訂造的治療方案顯示這些預測性生物標記在 個別病人的整體護理上不能替代的任務。本文會討論晚期胃腺癌中HER2的生物標記分析,以及轉移 性大腸癌中的KRAS突變。並探討生物標記在使用標靶治療中有關的問題。